| Literature DB >> 3118992 |
O Kloke1, R Becher, N Niederle.
Abstract
A previously untreated patient with benign phase chronic myelogenous leukaemia (CML) was treated with recombinant Interferon alpha-2 b. Haematological remission was induced for a total of twelve months. Thereafter, the patient developed resistance to Interferon alpha manifested by an increase in leucocyte counts despite dose escalation (up to 7 x 10(6) IU/day s.c.). Subsequent treatment with recombinant Interferon gamma failed to control myeloid proliferation. However, combined administration of both Interferon alpha and Interferon gamma resulted in a renewed haematological remission which lasted six months.Entities:
Mesh:
Substances:
Year: 1987 PMID: 3118992 DOI: 10.1007/bf00367463
Source DB: PubMed Journal: Blut ISSN: 0006-5242